OUR INVESTMENTS
We have been proud to participate in financings for the following revolutionary companies:
Therapeutics • CAMBRIDGE, MA
AXONIS Therapeutics is advancing breakthroughs in neuroscience to develop first-in-class precision therapies for neurological disorders.
Preclinical development → IND → Clinical trials → FDA approval
Key co-investor(s): venBio, Alexandria Venture Investments
Therapeutics • SAN francisco, CA
BioGraph55 is developing bispecific antibodies against a novel subset of immunosuppressive cells to treat resistant cancers.
Preclinical development → IND → Clinical trials → FDA approval
Key co-investor(s): Pfizer Venture Investments, Red Tree Venture Capital
Diagnostics • San Francisco, CA
Cytovale interrogates biomechanical properties of immune cells to rapidly diagnose sepsis and other severe immunological diseases.
Development → FDA clearance → Commercial launch
Key co-investor(s): Norwest Venture Partners, Breakout Ventures
Medical device • Chicago, IL
Dimension Inx creates advanced biomaterials and biofunctional 3D-printed implants for tissue regeneration and repair.
Development → FDA clearance → Commercial launch
Key co-investor(s): Prime Movers Lab, KdT Ventures
Therapeutics • New York, NY
IpiNovyx Bio develops ultra-selective immunoproteasome inhibitors for the treatment of autoimmune and inflammatory disorders.
Preclinical development → IND → Clinical trials → FDA approval
Key co-investor(s): Orange Grove Bio, Lilly Ventures
Therapeutics • Gaithersburg, MD
miRecule is a preclinical-stage biotechnology company developing RNA-based therapeutics for cancer and muscular dystrophy.
Preclinical development → IND → Clinical trials → FDA approval
Key co-investor(s): Alexandria Venture Investments
Therapeutics • NEW HAVEN, CT
Modifi Bio is a preclinical-stage company creating a new class of oral medicines that selectively kill cancer cells via direct DNA modification.
Preclinical development → IND → Clinical trials → FDA approval
Key co-investor(s): ACS BrightEdge Fund, HighCape Partners
Therapeutics • Oxford, UK
Ochre Bio is a computational biology and genetic medicine company developing novel RNA-based therapeutics for chronic liver diseases.
Preclinical development → IND → Clinical trials → FDA approval
Key co-investor(s): Khosla Ventures, LifeLink Ventures
Therapeutics • Indianapolis, IN
Scioto Biosciences is a clinical-stage biotechnology company developing bacterial therapeutics for GI and neurological diseases.
Preclinical development → IND → Clinical trials → FDA approval
Key co-investor(s): Elevate Ventures
Medical device • Chicago, IL
Simergent is building an automated peritoneal dialysis device that can provide cheaper, safer, and smarter home-based dialysis.
Development → FDA clearance → Commercial launch
Key co-investor(s): i2E Venture Capital
Other investments
London, uk
4BIO is a leading specialist investor in advanced modalities including cell, gene, RNA, and targeted therapies.
boulder, co
Afference leverages advances in neural engineering to create an artificial sense of touch.